Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Roivant Sciences Stock News

ROIVNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$10.19

At close: Apr 14 EDT

$10.28

0.090.88%

Pre-Market: 7:51 PM EDT

Roivant Sciences (ROIV) Forecast

News

Earnings Roivant Sciences (ROIV) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Roivant Sciences Stock News | NASDAQ:ROIV | Benzinga

Get the latest news on Roivant Sciences stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Roivant Sciences performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, March 19, 2025

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Vandana Singh - Mar 19, 2025, 12:39PM

Monday, March 03, 2025

Roviant Sciences Subsidiary, Genevant Science...
Benzinga Newsdesk - Mar 3, 2025, 9:16AM

Tuesday, February 11, 2025

HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk - Feb 11, 2025, 12:24PM

Monday, February 10, 2025

Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?
Piero Cingari - Feb 10, 2025, 1:52PM
Roivant Sciences Q3 Earnings Assessment
Benzinga Insights - Feb 10, 2025, 7:20AM
Roivant Sciences Q3 Adj $(0.20) Beats $(0.28)...
Benzinga Newsdesk - Feb 10, 2025, 7:09AM
Earnings Scheduled For February 10, 2025
Benzinga Insights - Feb 10, 2025, 3:32AM

Wednesday, January 01, 2025

Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences
Benzinga Insights - Jan 1, 2025, 10:00AM

Tuesday, December 03, 2024

Roivant Says Its Subsidiary Kinevant Sciences...
Benzinga Newsdesk - Dec 3, 2024, 7:06AM

Monday, November 18, 2024

'I'm One Of You' – How 'Anti-Woke' Warrior Vivek Ramaswamy Became A Billionaire At Only 38
Adrian Volenik - Nov 18, 2024, 9:46AM

Wednesday, November 13, 2024

The Analyst Landscape: 5 Takes On Roivant Sciences
Benzinga Insights - Nov 13, 2024, 4:01PM
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk - Nov 13, 2024, 2:00PM

Tuesday, November 12, 2024

Roivant Sciences Q2 2025 GAAP EPS $(0.31) Mis...
Benzinga Newsdesk - Nov 12, 2024, 7:29AM
Roivant Sciences Reports Q2 EPS Of $(0.31) Co...
Benzinga Newsdesk - Nov 12, 2024, 7:28AM
Earnings Scheduled For November 12, 2024
Benzinga Insights - Nov 12, 2024, 3:32AM

Friday, October 25, 2024

Dermavant Presents Final Data From ADORING 3 ...
Benzinga Newsdesk - Oct 25, 2024, 8:06AM

Wednesday, October 23, 2024

At Roivant Sciences, Eric Venker Chooses To Exercise Options, Resulting In $782K
Benzinga Insights - Oct 23, 2024, 11:02AM
Options Exercise: Eric Venker At Roivant Sciences Realizes $782K
Benzinga Insights - Oct 23, 2024, 11:00AM

Friday, October 18, 2024

Price Over Earnings Overview: Roivant Sciences
Benzinga Insights - Oct 18, 2024, 11:15AM

Thursday, October 03, 2024

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Oct 3, 2024, 4:31PM
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
Avi Kapoor - Oct 3, 2024, 8:43AM

Monday, September 23, 2024

Roivant Sciences And Organon Announce Merger ...
Benzinga Newsdesk - Sep 23, 2024, 4:29PM

Thursday, September 19, 2024

Cantor Fitzgerald Reiterates Overweight on Ro...
Benzinga Newsdesk - Sep 19, 2024, 10:41AM
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk - Sep 19, 2024, 6:21AM

Wednesday, September 18, 2024

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Vandana Singh - Sep 18, 2024, 3:20PM
Organon Will Acquire Dermavant, A Roivant Com...
Benzinga Newsdesk - Sep 18, 2024, 7:33AM

Wednesday, September 11, 2024

4 Analysts Assess Roivant Sciences: What You Need To Know
Benzinga Insights - Sep 11, 2024, 10:00AM
B of A Securities Maintains Neutral on Roivan...
Benzinga Newsdesk - Sep 11, 2024, 9:13AM
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk - Sep 11, 2024, 6:32AM

Tuesday, September 10, 2024

Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Vandana Singh - Sep 10, 2024, 2:21PM
Pulmovant, A Roivant Company, Announced The P...
Benzinga Newsdesk - Sep 10, 2024, 6:33AM

Monday, September 09, 2024

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Vandana Singh - Sep 9, 2024, 12:54PM
Cantor Fitzgerald Reiterates Overweight on Ro...
Benzinga Newsdesk - Sep 9, 2024, 9:03AM
Roivant Says Immunovant Reported Results From...
Benzinga Newsdesk - Sep 9, 2024, 7:06AM

Monday, August 19, 2024

HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk - Aug 19, 2024, 6:43AM

Thursday, August 08, 2024

Roivant Sciences shares are trading higher af...
Benzinga Newsdesk - Aug 8, 2024, 12:45PM
Roivant Sciences Q1 2025 Adj. EPS $(0.17) Bea...
Benzinga Newsdesk - Aug 8, 2024, 7:08AM

Wednesday, July 10, 2024

Piper Sandler Maintains Overweight on Roivant...
Benzinga Newsdesk - Jul 10, 2024, 10:09AM

Tuesday, June 18, 2024

Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Benzinga Insights - Jun 18, 2024, 11:00AM
Cantor Fitzgerald Reiterates Overweight on Ro...
Benzinga Newsdesk - Jun 18, 2024, 10:07AM

Friday, May 31, 2024

The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Benzinga Insights - May 31, 2024, 10:00AM
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk - May 31, 2024, 6:38AM

Thursday, May 30, 2024

Roivant Sciences Q4 2024 GAAP EPS $(0.19) Bea...
Benzinga Newsdesk - May 30, 2024, 7:02AM

Wednesday, May 22, 2024

Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
Vandana Singh - May 22, 2024, 8:04AM

Thursday, April 25, 2024

Roivant And Kinevant Sciences Complete Enroll...
Benzinga Newsdesk - Apr 25, 2024, 8:08AM

Monday, April 22, 2024

Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Benzinga Insights - Apr 22, 2024, 11:01AM
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk - Apr 22, 2024, 6:34AM

Wednesday, April 03, 2024

Goldman Sachs Maintains Buy on Roivant Scienc...
Benzinga Newsdesk - Apr 3, 2024, 11:18AM
HC Wainwright & Co. Maintains Buy on Roivant ...
Benzinga Newsdesk - Apr 3, 2024, 7:05AM
Deutsche Bank Maintains Buy on Roivant Scienc...
Benzinga Newsdesk - Apr 3, 2024, 5:14AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved